KM

Kestra Medical Technologies, Ltd.

KMTSHealthcareNASDAQ

Medical Instruments & Supplies · Last scanned Sep 9, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$95.1M
+59.0% YoY
Net Income
-$131.6M
-15.6% YoY
EBITDA
-$115.1M
-17.4% YoY
Free Cash Flow
-$75.8M

Scan Results

Daily timeframe
5 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 RSI OversoldRSI 26.4, below 30, stock may be oversold
Sep 2 RSI OversoldRSI 13.1, below 30, stock may be oversold
About Kestra Medical Technologies, Ltd.

Operating under the Medical Instruments & Supplies umbrella, Kestra Medical Technologies, Ltd. is a healthcare company. Kestra Medical Technologies, Ltd. The $1.50B market capitalization puts KMTS squarely in small-cap range for its industry. operates as a wearable medical device and digital healthcare company.

Where KMTS stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, KMTS finished 12.02% above its 150-day moving average ($22.97) and 9.12% above its 200-day moving average ($23.58). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is KMTS overbought or oversold?

At the September 3, 2026 close, KMTS's RSI(14) was 26.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$1.50B
Fwd P/E-12.69
EPS$-2.43
52W Change+40.4%
ROE-56.6%
Analysis

With $196.4M in cash and $46.8M in debt, KMTS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$75.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -56.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.

The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Kestra Medical Technologies, Ltd.'s trajectory.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms